Testing a new medication for kidney disease called focal segmental glomerulosclerosis

Plain-English translation of NCT07268638 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether a medication called can help treat focal segmental glomerulosclerosis (FSGS), a serious kidney disease that causes protein loss and kidney damage. Half of the participants will receive the medication for 6 months while the other half receive a placebo (a pill with no active ingredient). After that, everyone will receive the actual medication for another 6 months to see how well the treatment works and how safe it is.

Focal segmental glomerulosclerosis damages the kidney's filtering units and causes protein to leak into the urine, which can lead to kidney failure. Current treatments don't work well enough for everyone, so researchers are testing this medication to see if it can slow or stop the progression of kidney damage.

Do you qualify?

You likely qualify if…

you have been diagnosed with focal segmental glomerulosclerosis confirmed by a kidney biopsy
you are losing significant amounts of protein in your urine (at least 1 gram per day)
you have been taking a blood pressure medication (ACE inhibitor or ARB) at the highest dose you can tolerate for at least the past month
your kidney function is at a minimum level (estimated glomerular filtration rate of 25 or higher)
your kidney biopsy was done within the past 5 years, or was done earlier but you have a known genetic mutation linked to FSGS

You likely don't qualify if…

you have a rare, severe form of focal segmental glomerulosclerosis called collapsing FSGS
you have sickle cell disease
your diabetes is not well controlled (HbA1c greater than 8%)
your blood pressure is very high and hard to control (160/100 or higher)

What participation looks like

You will take a pill once daily that gradually increases to a target dose over the first 6 months. Half of participants will receive the actual medication while the other half receive a placebo — neither you nor the doctors will know which you're getting at first. After 6 months, everyone will know they're receiving the actual medication and continue taking it for another 6 months. Throughout the trial, you'll have regular visits to the clinic for blood tests, urine tests, and check-ins to monitor how you're doing.

AI-generated summary from trial data · Jul 14, 2026 · Not medical advice

Trial locations(23 sites)

United States

Investigator Site #2, Chula Vista, California

Investigator Site #14, Los Angeles, California

Investigator Site #12, San Dimas, California

Investigator Site #13, Arvada, Colorado

Investigator Site #17, Boca Raton, Florida